Evidence map›Paper›PMID 36033446›Full record

ReviewFrontiers in oncology2022

Radiation Oncology: Future Vision for Quality Assurance and Data Management in Clinical Trials and Translational Science.

Linda Ding, Carla Bradford, I-Lin Kuo, Yankhua Fan, Kenneth Ulin, Abdulnasser Khalifeh, Suhong Yu, Fenghong Liu, Jonathan Saleeby, Harry Bushe and 13 more

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Linda DingDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Carla BradfordDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
I-Lin KuoDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Yankhua FanDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Kenneth UlinDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Abdulnasser KhalifehDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Suhong YuDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Fenghong LiuDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Jonathan SaleebyDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Harry BusheDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Koren SmithDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Camelia BianciuDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Salvatore LaRosaDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Fred PriorDepartment of Biomedical Informatics, University of Arkansas, Little Rock, AR, United States.
Joel SaltzDepartment of Biomedical Informatics, Stony Brook University, Stony Brook, NY, United States.
Ashish SharmaDepartment of Biomedical Informatics, Emory University, Atlanta, GA, United States.
Mark SmyczynskiDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Maryann Bishop-JodoinDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Fran LaurieDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Matthew IandoliDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Janaki MoniDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
M Giulia CicchettiDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.
Thomas J FitzGeraldDepartment of Radiation Oncology, UMass Chan Medical School, Worcester, MA, United States.

Funding

TCIA Sustainment and Scalability - Platforms for Quantitative Imaging Informatics in Precision MedicineU24CA215109 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI BANERJEE, IMON, PRIOR, FRED WILLIAM · 2017 to 2021
$8.5M
NCI NIH HHS U24 CA215109
6 · The paper itself

Abstract

The future of radiation oncology is exceptionally strong as we are increasingly involved in nearly all oncology disease sites due to extraordinary advances in radiation oncology treatment management platforms and improvements in treatment execution. Due to our technology and consistent accuracy, compressed radiation oncology treatment strategies are becoming more commonplace secondary to our ability to successfully treat tumor targets with increased normal tissue avoidance. In many disease sites including the central nervous system, pulmonary parenchyma, liver, and other areas, our service is redefining the standards of care. Targeting of disease has improved due to advances in tumor imaging and application of integrated imaging datasets into sophisticated planning systems which can optimize volume driven plans created by talented personnel. Treatment times have significantly decreased due to volume driven arc therapy and positioning is secured by real time imaging and optical tracking. Normal tissue exclusion has permitted compressed treatment schedules making treatment more convenient for the patient. These changes require additional study to further optimize care. Because data exchange worldwide have evolved through digital platforms and prisms, images and radiation datasets worldwide can be shared/reviewed on a same day basis using established de-identification and anonymization methods. Data storage post-trial completion can co-exist with digital pathomic and radiomic information in a single database coupled with patient specific outcome information and serve to move our translational science forward with nimble query elements and artificial intelligence to ask better questions of the data we collect and collate. This will be important moving forward to validate our process improvements at an enterprise level and support our science. We have to be thorough and complete in our data acquisition processes, however if we remain disciplined in our data management plan, our field can grow further and become more successful generating new standards of care from validated datasets.

Indexed as

artificial intelligencecancer treatmentclinical trial dataclinical trial imagingclinical trialsquality assuranceradiation therapy (radiotherapy)translational medicine

Identifiers

PMID36033446
PMCPMC9399423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.